MarketBeat
22 Sept 2026, 06:02 UTC · 2h ago
Verdict
Headline takes no side. We score CMPS +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 84% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish · 0 new · 5 priced in
Compass Pathways expects to complete its rolling NDA submission for COMP360 in Q4 and targets a commercial launch in H1 2027.
Priced inreported during Deutsche Bank Healthcare Summit
So whatA H1 2027 launch implies a significant cash runway requirement through the next 2.5 years before peak revenue hits.
More positive than 92% of claims this week
The company targets an annualized cost for COMP360 in the $50,000 to $65,000 range, matching SPRAVATO's pricing.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Priced inreported during Deutsche Bank Healthcare Summit
So whatWith an estimated 3 doses annually, the per-dose price would be roughly $16,667 to $21,667.
More positive than 76% of claims this week
COMP360 is projected to require 2 to 4 doses annually, compared to SPRAVATO's 25 to 50 doses per year.
Priced inreported during Deutsche Bank Healthcare Summit
So whatThe lower treatment burden could drive higher adoption among the 3.9 million untreated TRD patients cited.
More positive than 62% of claims this week
Compass expects a monitoring period of six hours for COMP360, triple the two-hour requirement for SPRAVATO.
Priced inreported during Deutsche Bank Healthcare Summit
So whatIncreased site resource requirements may limit the speed of clinic certification and scalability in 2027.
More negative than 71% of claims this week
The company is conducting a Phase IIb/III trial in PTSD as a potential single registrational study.
Priced inreported during Deutsche Bank Healthcare Summit
More positive than 49% of claims this week
Which stocks this story touches
More positive than 84% of ticker scores this week
Positive updates on Phase III trial results, FDA rolling submission progress, and positive payer feedback for COMP360.
More negative than 72% of ticker scores this week
Its product SPRAVATO is framed as having a higher treatment burden compared to Compass Pathways' potential new offering.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
—
CMPS hasn't traded since this ran. Last close $15.01 (Sep 21); the reaction starts at the next open.
CMPS chart →